Evidence map›Paper›PMID 32152214›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020

The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them.

Martyn T Smith, Kathryn Z Guyton, Nicole Kleinstreuer, Alexandre Borrel, Andres Cardenas, Weihsueh A Chiu, Dean W Felsher, Catherine F Gibbons, William H Goodson, Keith A Houck and 13 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Unveiling toxicological adverse outcomes: toward construction and simulation of large-scale networks.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Systematic evaluation of the evidence base on ethylCurrent research in toxicology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. A workflow for human health hazard evaluation using transcriptomic data and Key Characteristics-based gene sets.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  15. Article
  16. Review
  17. Mapping assays to the key characteristics of carcinogens to support decision-making.Database : the journal of biological databases and curation · 2025
    Article
  18. Review
  19. The key characteristics concept.Current opinion in toxicology · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Martyn T SmithDivision of Environmental Health Sciences, School of Public Health, University of California Berkeley, Berkeley, California. martynts@berkeley.edu.
Kathryn Z GuytonMonographs Programme, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-7825-1262
Nicole KleinstreuerDivision of Intramural Research, Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina.
Alexandre BorrelDivision of Intramural Research, Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina.ORCID 0000-0001-6499-4540
Andres CardenasDivision of Environmental Health Sciences, School of Public Health, University of California Berkeley, Berkeley, California.ORCID 0000-0003-2284-3298
Weihsueh A ChiuVeterinary Integrative Biosciences, Texas A&M University, College Station, Texas.ORCID 0000-0002-7575-2368
Dean W FelsherDivision of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, Stanford, California.
Catherine F GibbonsOffice of Research and Development, US Environmental Protection Agency, Washington, D.C.
William H GoodsonCalifornia Pacific Medical Center Research Institute, San Francisco, California.
Keith A HouckOffice of Research and Development, US Environmental Protection Agency, Research Triangle Park, North Carolina.ORCID 0000-0002-0055-2249
Agnes B KaneDepartment of Pathology and Laboratory Medicine, Alpert Medical School, Brown University, Providence, Rhode Island.
Michele A La MerrillDepartment of Environmental Toxicology, University of California, Davis, California.ORCID 0000-0002-5720-5862
Herve LebrecComparative Biology & Safety Sciences, Amgen Research, Amgen Inc., Thousand Oaks, California.
Leroy LoweGetting to Know Cancer, Truro, Nova Scotia, Canada.
Cliona M McHaleDivision of Environmental Health Sciences, School of Public Health, University of California Berkeley, Berkeley, California.ORCID 0000-0002-8520-6117
Sheroy MinocherhomjiComparative Biology & Safety Sciences, Amgen Research, Amgen Inc., Thousand Oaks, California.
Linda RieswijkDivision of Environmental Health Sciences, School of Public Health, University of California Berkeley, Berkeley, California.ORCID 0000-0002-6106-1347
Martha S SandyOffice of Environmental Health Hazard Assessment, California Environmental Protection Agency, Oakland, California.ORCID 0000-0001-8468-5745
Hideko SoneYokohama University of Pharmacy and National Institute for Environmental Studies, Tsukuba Ibaraki, Japan.
Amy WangOffice of the Report on Carcinogens, Division of National Toxicology Program, The National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.
Luoping ZhangDivision of Environmental Health Sciences, School of Public Health, University of California Berkeley, Berkeley, California.
Lauren ZeiseOffice of Environmental Health Hazard Assessment, California Environmental Protection Agency, Oakland, California.
Mark FieldenExpansion Therapeutics Inc, San Diego, California.

Funding

Training CoreP42ES004705 · NIEHS · UNIVERSITY OF CALIFORNIA BERKELEY · PI MCHALE, CLIONA · 1987 to 2025
$74.6M
Integrated Health Assessments for the Division of the National Toxicology ProgramZICES103317 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI ROONEY, ANDREW · 2020 to 2021
$9.6M
NIEHS NIH HHS P42 ES004705World Health Organization 001
6 · The paper itself

Abstract

The key characteristics (KC) of human carcinogens provide a uniform approach to evaluating mechanistic evidence in cancer hazard identification. Refinements to the approach were requested by organizations and individuals applying the KCs. We assembled an expert committee with knowledge of carcinogenesis and experience in applying the KCs in cancer hazard identification. We leveraged this expertise and examined the literature to more clearly describe each KC, identify current and emerging assays and

Indexed as

BiomarkersCarcinogensHumansNeoplasmsBiomarkersCarcinogens

Identifiers

PMID32152214
PMCPMC7483401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.